Abstract
Objectives: To investigate the possible effect of abnormal placentation disorders such as preeclampsia (PE), pregnancy induced hypertension (PIH) and intrauterine growth restriction (IUGR) on erythropoietin (EPO) serum concentration in women in the first trimester of pregnancy.
Material and methods: A prospective study was performed in a group of pregnant women between 11 and 13+6 weeks’ gestation. Serum concentration of EPO, beta HCG, PAPP-A and PlGF was measured. Mean arterial pressure (MAP) and uterine artery pulsatility index was calculated.
Results: A group of 198 analyzed patients was divided into three groups depending on pregnancy outcome: abnormal placentation group (n=30), macrosomia (n=13) and control group (n=155). EPO concentrations between the three groups of patients revealed that they differ significantly (F=15.172, P<0.001). EPO concentration is significantly higher in abnormal placentation patients compared to the control group (P<0.001) and macrosomia group (P=0.004). The most significant increase in EPO concentration was detected within patients with PIH. Also the uterine artery pulsatility index was positively correlated with EPO concentration (P<0.01).
Conclusions: First-trimester maternal EPO concentration might be considered as a possible marker of abnormal placentation disorders and should be given more attention in future prospective studies.
Acknowledgments
The study was supported by the Ministry of Science and Higher Education scientific grant number NN407115640.
References
[1] Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH. Maternal plasma cell-free fetal and maternal DNA at 11–13 weeks’ gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther. 2013;33:215–23.10.1159/000346806Search in Google Scholar PubMed
[2] Bijok J, Gorzelnik K, Massalska D, Ilnicka A, Pawlowska B, Zimowski JG, et al. [Non-invasive prenatal diagnosis of the most common aneuploidies with cell-free fetal DNA in maternal serum–preliminary results] Nieinwazyjna diagnostyka prenatalna najczestszych aneuploidii na podstawie plodowego DNA we krwi matki – doniesienie wstepne. Ginekol Pol. 2014;85:208–13.Search in Google Scholar
[3] Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther. 2011;29:183–96.10.1159/000324320Search in Google Scholar PubMed
[4] Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn. 2011;31:66–74.10.1002/pd.2660Search in Google Scholar PubMed
[5] Roberge S, Giguere Y, Villa P, Nicolaides K, Vainio M, Forest JC, et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2014;31:e3.10.1055/s-0033-1343351Search in Google Scholar
[6] Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM. Expression of erythropoietin by the human placenta. FASEB J. 1996;10:760–8.10.1096/fasebj.10.7.8635693Search in Google Scholar PubMed
[7] Nangaku M, Eckardt KU. Hypoxia and the HIF system in kidney disease. J Mol Med (Berl). 2007;85:1325–30.10.1007/s00109-007-0278-ySearch in Google Scholar PubMed
[8] Clapp JF, Little KD, Widness JA. Effect of maternal exercise and fetoplacental growth rate on serum erythropoietin concentrations. Am J Obstet Gynecol. 2003;188:1021–5.10.1067/mob.2003.232Search in Google Scholar PubMed
[9] Riikonen S, Saijonmaa O, Jarvenpaa AL, Fyhrquist F. Serum concentrations of erythropoietin in healthy and anaemic pregnant women. Scand J Clin Lab Invest. 1994;54:653–7.10.3109/00365519409087546Search in Google Scholar PubMed
[10] Hershkovitz R, Ohel I, Sheizaf B, Nathan I, Erez O, Sheiner E, et al. Erythropoietin concentration among patients with and without preeclampsia. Arch Gynecol Obstet. 2005;273:140–3.10.1007/s00404-005-0013-2Search in Google Scholar PubMed
[11] Beguin Y, Lipscei G, Oris R, Thoumsin H, Fillet G. Serum immunoreactive erythropoietin during pregnancy and in the early postpartum. Br J Haematol. 1990;76:545–9.10.1111/j.1365-2141.1990.tb07914.xSearch in Google Scholar PubMed
[12] Ireland R, Abbas A, Thilaganathan B, Melbye O, Snjiders R, Layton M, et al. Fetal and maternal erythropoietin levels in normal pregnancy. Fetal Diagn Ther. 1992;7:21–5.10.1159/000263645Search in Google Scholar PubMed
[13] Kowalska-Kanka A, Maciejewski T, Niemiec KT. The role and regulation of secretion of erythropoietin in pregnancy. Medycyna wieku rozwojowego. 2013;17:270–5.Search in Google Scholar
[14] McMullin MF, White R, Lappin T, Reeves J, MacKenzie G. Haemoglobin during pregnancy: relationship to erythropoietin and haematinic status. Eur J Haematol. 2003;71:44–50.10.1034/j.1600-0609.2003.00085.xSearch in Google Scholar PubMed
[15] Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, et al. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol. 2001;106 (2 Suppl 2):215–22.Search in Google Scholar
[16] Schneider H, Malek A. Lack of permeability of the human placenta for erythropoietin. J Perinat Med. 1995;23:71–6.10.1515/jpme.1995.23.1-2.71Search in Google Scholar PubMed
[17] Fahnenstich H, Dame C. Erythropoietin concentrations and erythropoiesis in newborns suffering from renal agenesis and congenital kidney diseases. Eur J Pediatr. 1996;155:185–8.10.1007/BF01953935Search in Google Scholar PubMed
[18] Girsen A, Makikallio K, Hiilesmaa V, Hamalainen E, Teramo K, Rasanen J. The relationship between human fetal cardiovascular hemodynamics and serum erythropoietin levels in growth-restricted fetuses. Am J Obstet Gynecol. 2007;196:467 e1-6.10.1016/j.ajog.2006.12.032Search in Google Scholar PubMed
[19] Goldstein JD, Garry DJ, Maulik D. Obstetric conditions and erythropoietin levels. Am J Obstet Gynecol. 2000;182:1055–7.10.1067/mob.2000.105389Search in Google Scholar PubMed
[20] Kaupke CJ, Vaziri ND, Powers DR, Gonzales E. Erythropoietin in preeclampsia. Obstet Gynecol. 1991;78:795–9.Search in Google Scholar
[21] Kosinski P, Samaha RB, Bomba-Opon DA, Kozlowski S, Lipa M, Kaczynski B, et al. Reference values for placental growth factor (PlGF) concentration and uterine artery doppler pulsatility index (PI) at 11–13(+6) weeks of gestation in the Polish population. Ginekol Pol. 2014;85:488–93.10.17772/gp/1758Search in Google Scholar PubMed
The authors stated that there are no conflicts of interest regarding the publication of this article.
©2016 by De Gruyter
